Japan Medical Dynamic Marketing, INC.

2026/11/04 12:33 Updated
Market Cap: $96.6M (¥15.3B)
Stock Price: $3.67 (¥581)
Exchange Rate: 1 USD = ¥158.48

Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027

Consolidated results for the second quarter of the fiscal year ending March 2027: net sales 10,437 million yen, operating loss 1,036 million yen, interim net loss attributable to owners of parent 1,749 million yen. Cost of sales ratio rose to 44.4%. Both Japan and U.S. business segments recorded losses. Total assets at the end of the interim period were 33,528 million yen and net assets were 23,070 million yen. Full-year forecasts for 2027 were revised.

Importance:
Page Updated: November 4, 2026
IR Disclosure Date: November 4, 2026

Key Figures

  • Net Sales: 10,437 million yen (Year-over-Year -10.1%)
  • Operating Loss: -1,036 million yen
  • Interim Net Loss Attributable to Owners of Parent: -1,749 million yen
  • Total Assets: 33,528 million yen
  • Net Assets: 23,070 million yen

AI要約

Overview of Results

For the period, consolidated net sales amounted to 10,437 million yen, a 10.1% decrease year-over-year. The decline reflects reduced demand at the U.S. subsidiary, foreign exchange impacts, and deteriorating sales across product lines, resulting in an operating loss. Both Japan and U.S. segments posted losses. The cost of sales ratio rose to 44.4%, mainly due to increased burden of fixed manufacturing costs and higher import costs from yen depreciation. The interim net loss expanded to 1,749 million yen. The financial position declined to total assets of 33,528 million yen and net assets of 23,070 million yen at the interim period end. Supplementary financial materials are available and an earnings presentation will be held.

Outlook and Matters Going Forward

The full-year earnings forecast for the fiscal year ending March 2027 has been revised and disclosed. Subsequent events in the interim period include rationalization and personnel reductions at the U.S. subsidiary, and retirement-related expenses are expected to be recorded in fiscal 2027. There is a possibility of further disclosures regarding shareholder return policy and additional revisions to earnings guidance. For both Japan and U.S. segments, restoring profitability remains a challenge; controlling selling, general and administrative expenses and improving cost structure are key.

Net Sales Trend

Operating Income Trend

Segment Revenue Composition

Cost of Sales Ratio and SG&A Ratio Trend

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Japan Medical Dynamic Marketing, INC.

Company overview · Stock price · Financial data · All IR

View company page →